Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis
Conditions
Interventions
Metronidazole oral tablets 500mg
1% SPL7013 Gel
+1 more
Locations
45
United States
University of Alabama
Birmingham, Alabama, United States
Montgomery Women's Health Associates
Montgomery, Alabama, United States
Lynn Institute of the Ozarks
Little Rock, Arkansas, United States
Precision Research Institute
San Diego, California, United States
Women's Health Care
San Diego, California, United States
Lynn Institute of the Rockies
Colorado Springs, Colorado, United States
Start Date
October 13, 2014
Primary Completion Date
December 9, 2016
Completion Date
February 22, 2017
Last Updated
July 22, 2019
NCT07394777
NCT06472765
NCT06469164
NCT06470906
NCT06123299
NCT02432404
Lead Sponsor
Starpharma Pty Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions